Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors

Relay Therapeutics, Inc.

2025-Q3 EPS reported -$1.30 revenue$8,355,000

Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.
Cash, cash equivalents and investments $596.4M at Sep 30, 2025; expected to fund operations into 2029.
R&D expenses $68.3M, down from $76.6M YoY on streamlining and cost avoidance.
Board appointed Lonnel Coats and Habib Dable, former biotech CEOs, effective Nov 4, 2025.
Continued Phase 3 ReDiscover-2 trial and Phase 1/2 ReInspire trial in vascular malformations.

item 2.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.